[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periprosthetic-joint-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periprosthetic-joint-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,71,97,117,139,166,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100525813","phase-3-infection-prophylaxis-in-total-joint-replacement-100525813",false,"NCT06126614","Infection Prophylaxis in Total Joint Replacement","Prospective Randomized Evaluation of Emerging Novel Treatments for Infection Prophylaxis in Total Joint Replacement (PREVENT-iT)","PREVENT-iT","Inclusion Criteria:\n\n1. Patients 18 years of age or older.\n2. Undergoing primary or aseptic revision TJR.\n3. No contraindications to study interventions.\n4. Informed consent (participant or substitute decision maker) obtained and willing to comply with the protocol.\n\nExclusion Criteria:\n\n1. Received antibiotics for any reason in the two weeks prior to their TJR.\n2. Chronic or acute infection at or near the TJR site.\n3. Prior history of periprosthetic joint infection including any reoperation due to infection.\n4. Undergoing surgery for a diagnosis of a fracture.\n5. Open infected wounds on affected limb.\n6. Undergoing bilateral TJR.\n7. Currently enrolled in a study that does not permit co-enrollment.\n8. Prior enrollment in the trial including the pilot study\n9. Any condition or circumstance, which in the opinion of the Investigator, interferes with assessments or completion of the trial.","ALL","18 Years",{"count":20,"type":21},21006,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Osteoarthritis (OA) is the most common cause of disability in older adults worldwide affecting 7% of the global population, or more than 500 million people globally. Total joint replacements (TJR) can help bring relief to those with osteoarthritis when other treatment options are no longer helpful. Infection is the main reason hip and knee replacements \"fail\". Failure leads to repeat surgeries that are often more complicated and less likely to be successful than the first surgery. Reducing the risk of infection is extremely important, antiseptic washes and antibiotics may help us do that. After joint replacement surgery, orthopaedic surgeons wash and clean the surgical wound to lower the risk of infection. The goal of this clinical trial is to determine if the use of antiseptic solutions to wash the surgical site and placing an antibiotic directly into the wound will reduce the number of infections requiring reoperation. Patients having total joint replacements will be randomized (like flipping a coin) to receive 6 possible combinations of washes and \u002F or antibiotics. Participants will be followed for one year after TJR to compare the rate of infection in each group.",[27],"Periprosthetic Joint Infection",[29],"Arthroplasty","RECRUITING","2026-05-20",{"date":33,"type":34},"2026-05-22","ACTUAL",{"date":36,"type":34},"2024-05-07",{"date":38,"type":21},"2028-11",{"name":40,"class":41},"Hamilton Health Sciences Corporation","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100549010","phase-2-study-to-evaluate-the-remedy-spectrum-gv-im-spacer-nail-in-the-treatment-of-ankle-related-infections-100549010","NCT06428448","Study to Evaluate the REMEDY SPECTRUM GV IM Spacer Nail in the Treatment of Ankle-Related Infections","A Prospective, Multi-Center Study to Evaluate the Safety and Effectiveness of the REMEDY SPECTRUM GV IM Spacer Nail in the Treatment of Ankle-Related Infections","Inclusion Criteria:\n\n1. Be ≥ 21 years of age\n2. Have an ankle-related infection\n3. Is skeletally mature, as evidenced by closed epiphyses.\n4. Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study\n5. Be willing and able to comply with all study procedures including all pre-operative, post-operative requirements\n6. If female and of child-bearing potential, must have a negative pregnancy test prior to the surgical procedure and no intention of becoming pregnant until study completion.\n\nExclusion Criteria:\n\n1. Infections that do not involve the ankle\n2. Have a known immunodeficiency; including subjects who are receiving or have received immunosuppressants, immunostimulating agents or radiation therapy within 6 months prior to surgery\n3. Affected limb is dysvascular\n4. Where adequate soft-tissue coverage cannot be achieved\n5. Have any mental or psychological disorder that would impair their ability to complete the study questionnaires\n6. Are currently pregnant or breastfeeding, or planning to become pregnant or breastfeed any time during the course of the study\n7. Are currently a prisoner\n8. Have any medical condition or other circumstances, in the judgment of the Investigator, that might interfere with the ability to return for follow-up visits, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative activities.\n9. History of vancomycin or gentamicin allergy\n10. Are implanted with other antibiotic eluting products.",true,"21 Years",{"count":53,"type":21},60,[55],"PHASE2","This study is being conducted to evaluate the safety and effectiveness of the REMEDY SPECTRUM IM Spacer Nail in the treatment of ankle-related infections. The study is expected to take approximately 18 months from first subject enrolled to the last follow-up visit. It will have a 12-month enrollment period and a 6-month follow-up. This study is a Prospective, multicenter, single-arm clinical trial. All subjects enrolled in this study will receive the REMEDY SPECTRUM IM Spacer Nail.",[27],[59],"Ankle-related Infections","2026-05-15",{"date":62,"type":34},"2026-05-19",{"date":64,"type":34},"2026-02-01",{"date":66,"type":21},"2027-12",{"name":68,"class":69},"OsteoRemedies, LLC","INDUSTRY",3,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100617022","rifampin-combined-antibiotic-therapy-for-staphylococcal-pji-100617022","NCT07313215","Rifampin-combined Antibiotic Therapy for Staphylococcal PJI","The Efficacy and Complications of Rifampin-combined Antibiotic Therapy for Staphylococcal Periprosthetic Joint Infections（PJI）: A Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed as PJI according to the MSIS criteria\n\n  * The pathogenic bacteria were identified as Staphylococcus through microbial culture and drug sensitivity tests were conducted\n\n    * There are complete clinical data ④ Age under 80 years old, without serious complications or immunosuppressive status ⑤ The patient voluntarily participated in this study and was physically and mentally tolerant of the treatment process and various tests in this study. They have signed the informed consent form and passed the review of the ethics committees of all hospitals participating in this study\n\nExclusion Criteria:\n\n* Those with chronic inflammation in other parts of the body before the operation\n\n  * Non-staphylococcal infection or mixed infection\n\n    * The patient has other diseases that may affect the outcome, such as immune deficiency or liver and kidney dysfunction ④ Those with an expected lifespan of less than half a year ⑤ The researcher determined that the patient no longer met the criteria of this study due to compliance issues","80 Years",{"count":80,"type":21},428,[82],"NA","This is a prospective, multicenter, randomized controlled study. Patients were evaluated through inclusion and exclusion criteria. Patients who meet the conditions will sign an informed consent form. After DAIR surgery, they will be treated with intravenous antibiotics for 1-2 weeks and then randomly assigned to one of the following two groups: Antibiotic treatment group: All enrolled patients will be treated with antibiotics (fluoroquinolones or linezolid) for 3 months based on the results of microbial culture and drug sensitivity after surgery. Rifampicin combined with antibiotics treatment group: In addition to the above-mentioned antibiotics, all enrolled patients were treated with rifampicin for 3 months after the operation. The infection control rates of the two groups were judged through at least 2-year follow-up after the operation.The study will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting parallel group randomised trials. Ethical approval will be obtained from each institution. Written informed consent will be obtained from all participants to ensure their voluntary participation and understanding of the study.",[27],[27,86,87],"Debride ment, antibiotics, and implant retention","Revision","2025-12-17",{"date":90,"type":34},"2025-12-31",{"date":92,"type":34},"2025-11-13",{"date":94,"type":21},"2027-12-18",{"name":96,"class":41},"First Affiliated Hospital of Fujian Medical University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":42},"100536743","a-diagnostic-test-accuracy-study-comparing-biopsy-to-aspiration-in-shoulder-and-elbow-arthroplasty-revision-surgery-base-study-100536743","NCT06268795","A Diagnostic Test Accuracy Study Comparing Biopsy to Aspiration in Shoulder and Elbow Arthroplasty Revision Surgery (BASE Study)","Inclusion Criteria:\n\n* Aged: 18 years or older.\n* A participant is willing and able to give informed consent for participation in the study.\n* Patient undergoing revision shoulder or elbow arthroplasty surgery.\n* Previous anatomic total shoulder arthroplasty (TSA), shoulder hemiarthroplasty (HA), reverse total shoulder arthroplasty (RTSA), total elbow arthroplasty (TEA), distal humeral hemiarthroplasty (DHH) and radial head arthroplasty (RHA).\n\nExclusion Criteria:\n\n* Refusal of consent.\n* Antibiotic treatment was not stopped 2 weeks before aspiration or biopsy.\n* Pregnancy.\n* Part of any other trial with similar interventions unless previously agreed on with investigators.",{"count":104,"type":21},244,"OBSERVATIONAL","The aim of this study is to compare the diagnostic accuracy of percutaneous aspiration against open biopsy, using microbiological and histological methods, for the detection of shoulder and elbow periprosthetic joint infection (PJI). This is to establish the utility of pre-operative joint aspiration in the treatment pathway for shoulder and elbow PJI.",[27],"2025-07-23",{"date":110,"type":34},"2025-07-28",{"date":112,"type":34},"2024-03-20",{"date":114,"type":21},"2028-09-01",{"name":116,"class":41},"Wrightington, Wigan and Leigh NHS Foundation Trust",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":123,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":42},"100588532","phase-1-phage-therapy-for-the-treatment-of-a-chronic-enterococcus-faecium-periprosthetic-joint-infection-100588532","NCT06942624","Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection","Inclusion Criteria:\n\nThis N-of-1 Phage therapy is designed for one patient who meet the following conditions\n\n* Willingness to provide signed and dated informed consent form to participate in the clinical study\n* Chronic prosthetic joint infection\n* History of multiple surgical and medication managements with no success\n\nExclusion Criteria:\n\n* below 18 years of age","MALE",{"count":42,"type":21},[126,55],"PHASE1","This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosthetic joint infection (PJI) of the hip. We have exhausted all surgical and medical management of PJI for our patient.\n\nThe phage will be administered to the study patient during a 14 days period via intravenous and intra-articular. The patient will be monitored in clinic for up to 1 year.",[27],"NOT_YET_RECRUITING","2025-04-17",{"date":132,"type":34},"2025-04-24",{"date":134,"type":21},"2025-05",{"date":136,"type":21},"2026-06",{"name":138,"class":41},"Orthopaedic Innovation Centre",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":50,"sex":123,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":42},"100551798","optimizing-infection-prophylaxis-prior-to-shoulder-surgery-100551798","NCT06464770","Optimizing Infection Prophylaxis Prior to Shoulder Surgery","Inclusion Criteria:\n\n* English speaking\n\nExclusion Criteria:\n\n* Self report very sensitive skin\n* Allergic to chlorhexidine\n* Used antibiotics in the last three months\n* Used acne treatment in the last three months\n* Wounds on your shoulders","89 Years",{"count":147,"type":21},40,[82],"The goal of this interventional study is to determine the amount of skin C. acnes reduction with increased pressure during the chlorhexidine gluconate, brand name ChloraPrep, application. The main question it aims to answer is:\n\nDoes changing the pressure applied during the ChloraPrep application impact the amount of C. acnes bacteria on the skin after one hour? Researchers will compare ChloraPrep applied at a pressure similar to a gentle wipe to ChloraPrep applied at a pressure similar to a massage to see if wash the amount of C. acnes on the skin after one hour is different.\n\nParticipants will have one shoulder washed with ChloraPrep using pressure meant to impact the dermal layer, similar to a gentle wipe, and the other shoulder washed with ChloraPrep using pressure meant to impact the subdermal layer, similar to a massage. Participants will have swabs taken of their skin before the ChloraPrep application and again one hour after application to look for the amount of C. acnes on the skin.",[151,27],"Arthroplasty Shoulder",[153,154,155,156],"periprosthetic joint infection","cutibacterium","shoulder arthroplasty","chlorhexidine","2024-12-04",{"date":159,"type":34},"2024-12-05",{"date":161,"type":34},"2024-08-31",{"date":163,"type":21},"2027-12-31",{"name":165,"class":41},"University of Washington",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":42},"100530676","preoperative-daptomycin-prophylaxis-in-two-stage-exchange-arthroplasty-a-prospective-randomized-double-blinded-trial-100530676","NCT06189885","Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial","Preoperative Daptomycin Prophylaxis for Preventing Gram-Positive or Methicillin-Resistant Staphylococcus Aureus Infection in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial","Inclusion Criteria:\n\n1. Patients aged 18 or older with an infection that meets the 2018 International Consensus Meeting (ICM) criteria7 at the time of the first-stage resection arthroplasty with a gram-positive organism, especially MRSA.\n2. Will undergo a second stage of reimplantation.\n\nExclusion Criteria:\n\n1. Patients with a fungal infection or culture-negative infections\n2. Known allergies to Cefazolin, Daptomycin, or Vancomycin.\n3. Currently receiving surgical treatment for acute postoperative or acute hematogenous PJI.\n4. Chronic kidney disease (Creatinine Clearance Rate \\[CCR\\] \\\u003C 30 ml\u002Fmin\u002F1.73m2)","90 Years",{"count":175,"type":21},184,[82],"The gold standard for treating prosthetic joint infection (PJI) is two-stage exchange arthroplasty. This includes the first stage of debridement and removal of the artificial joint, and the second stage of reimplantation of the artificial joint. Methicillin-resistant staphylococcus aureus (MRSA) infection is one of the factors leading to the failure of artificial joint infection treatment. Before the second stage of the joint surgery, the surgeon will prescribe prophylactic antibiotics based on previous bacterial cultures. The usual preoperative antibiotic is a first-generation cephalosporin antibiotic. If it is MRSA, vancomycin will be given. Increasingly, literature reports link prosthetic joint infections to MRSA, but no changes have been made to the routine recommendation for MRSA prophylactic antibiotic use.\n\nDaptomycin is a cyclic lipopeptide antibiotic that can rapidly penetrate biofilms and bones, and its safety and tolerability have been confirmed. Therefore, it can effectively combat Gram-positive organisms, including MRSA. Daptomycin has many characteristics of an ideal prophylactic: short infusion time, low adverse events during administration, and a range limited to Gram-positive organisms. We aim to assess whether adding antibiotics that cover MRSA would reduce prosthetic joint infections and increase surgical success rates, in addition to the standard recommended prophylactic antibiotics. Thus, this prospective randomized trial is designed to assess, besides using the first-generation cephalosporin antibiotic, the effects of adding an antibiotic with MRSA coverage (Daptomycin vs. Vancomycin).",[27],"2023-12-19",{"date":181,"type":34},"2024-01-05",{"date":183,"type":21},"2024-08-01",{"date":185,"type":21},"2026-07-31",{"name":187,"class":41},"Chang Gung Memorial Hospital",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":198,"studyType":105,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":42},"100461106","prospective-cohort-study-on-antibiotic-course-and-efficacy-after-two-stage-revision-in-pji-100461106","NCT05284318","Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.","Effect of Antibiotic Treatment Course on Clinical Outcome After Two-stage Revision of Prosthetic Joint Infection: A Prospective Cohort Study.","PACER-PJI","Inclusion Criteria:\n\n\\- 1. A diagnosis of PJI was made according to MSIS criteria. 2. Received spacer implantation and a full course of antibiotic treatment (at least 6 weeks), the patient was clinically determined to have infection control and underwent secondary joint revision.\n\n3\\. Age ≥18 years old. 4. The patient voluntarily participated in the study, and was physically and mentally tolerant to the treatment process and various tests of the study. He has signed an informed consent form and passed the examination of all the hospital ethics committees participating in the study.\n\nExclusion Criteria:\n\n* 1\\. Follow-up data not available. 2. Researchers judge that patients no longer meet the standards of the study due to compliance problems",{"count":197,"type":21},500,"2 Years","This is a multicenter prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before phase II revision surgery. Eligible patients will be included in this study after signing the informed consent form. After the second stage revision, according to the patient's symptoms and examination results, the attending physician used a reasonable antibiotic treatment scheme (including intravenous and oral medication). All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the time points of 1, 3, 6, 12, 18 and 24 months after the start of antibiotic treatment after phase II revision. The infection control rate of patients was evaluated by follow-up at least 2 years after operation, so as to analyze the effect of antibiotic treatment course after two-stage revision of periprosthetic joint infection.",[27,201],"Anti-Bacterial Agents",[203,204,201],"Periprosthetic joint infection","Second-stage revision","2022-03-09",{"date":207,"type":34},"2022-03-17",{"date":209,"type":34},"2021-12-01",{"date":211,"type":21},"2026-12-31",{"name":96,"class":41}]